AstraZeneca's PD-L1 Works, But Probably Not Enough For Lung Cancer Filing
This article was originally published in Scrip
AstraZeneca PLC's chief medical officer has warned once again that a trial of the company's PD-L1 inhibitor durvalumab will not provide strong enough data to support a regulatory submission for the drug as a standalone treatment for advanced lung cancer. However, preliminary findings from the company's lead monotherapy trial, ATLANTIC, show that it does work.
Register for our free email digests: